Login to Your Account

Biosimilars Are Not Yet a Threat to Brand Patents

By Mari Serebrov

Wednesday, March 9, 2011
WASHINGTON – Whether the U.S. Supreme Court's refusal to hear a pay-for-delay patent settlement case Monday will affect biologics depends largely on how the FDA shapes the biosimilar regulatory pathway in the future.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription